Showing 1 - 20 results of 547 for search '"ТАРГЕТИРОВАНИЕ"', query time: 0.90s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
    Academic Journal

    Source: Relevant issues of the Russian Federation law enforcement's activity; 72-74 ; Актуальные проблемы деятельности правоохранительных органов Российской Федерации; 72-74

    File Description: text/html

    Relation: info:eu-repo/semantics/altIdentifier/isbn/978-5-907965-30-0; https://phsreda.com/e-articles/10706/Action10706-126899.pdf; Алексеев И.В. Безопасность персональных данных: правовые аспекты и технические решения / И.В. Алексеев, А.А. Иванов. – М.: Юрайт, 2022. – 312 с.; Иванов И.И. Безопасность персональных данных в эпоху больших данных / И.И. Иванов // Вестник Московского университета. Серия 11: Право. – 2023. – №3. – С. 23–34.; Сидоров К.Г. Правовые основы защиты персональных данных в Российской Федерации / К.Г. Сидоров. – М.: Проспект, 2023. – 352 с.; Фёдоров О.Н. Технологии шифрования и анонимности в сети Интернет / О.Н. Фёдоров. – М.: Горячая линия-Телеком, 2024. – 224 с.; https://phsreda.com/article/126899/discussion_platform

  7. 7
    Academic Journal

    Source: Surgery and Oncology; Том 15, № 1 (2025); 11-17 ; Хирургия и онкология; Том 15, № 1 (2025); 11-17 ; 2949-5857

    File Description: application/pdf

    Relation: https://www.onco-surgery.info/jour/article/view/776/489; Ma J., Mo Y., Tang M. et al. Bispecific Antibodies: From Research to Clinical Application. Front Immunol 2021;12:626616. https://doi.org/10.3389/fimmu.2021.626616; Yu S., Li A., Liu Q. et al. Recent advances of bispecific antibodies in solid tumors. J Hematol Oncol 2017;10(1):155. https://doi.org/10.1186/s13045-017-0522-z; Xu G., Luo Y., Wang H. et al. Therapeutic bispecific antibodies against intracellular tumor antigens. Cancer Lett 2022;538:215699. https://doi.org/10.1016/j.canlet.2022.215699; Wei J., Yang Y., Wang G., Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol 2022;13:1035276. https://doi.org/10.3389/fimmu.2022.1035276; Moon D., Tae N., Park Y. et al. Development of bispecific antibody for cancer immunotherapy: focus on T cell engaging antibody. Immune Netw 2022;22(1):e4. https://doi.org/10.4110/in.2022.22.e4; Blanco B., Domínguez-Alonso C., Alvarez-Vallina L. Bispecific immunomodulatory antibodies for cancer immunotherapy. Clin Canc Res 2021;27(20):5457–64. https://doi.org/10.1158/1078-0432.ccr-20-3770; Marin-Acevedo J.A., Kimbrough E.O., Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncology 2021;14(1):45. https://doi.org/10.1186/s13045-021-01056-8; Wu Y., Yi M., Zhu S. et al. Recent advances and challenges of bispecific antibodies in solid tumors. Exp Hematol Oncol 2021;10:56. https://doi.org/10.1186/s40164-021-00250-1; Wang Q., Chen Y., Park J. et al. Design and Production of Bispecific Antibodies. Antibodies (Basel, Switzerland) 2019;8(3):43. https://doi.org/10.3390/antib8030043; Madsen A.V., Pedersen L.E., Kristensen P., Goletz S. Design and engineering of bispecific antibodies: insights and practical considerations. Front Bioeng Biotech 2024;12:1352014. https://doi.org/10.3389/fbioe.2024.1352014; Keri D., Walker M., Singh I. et al. Next generation of multispecific antibody engineering. Antib Ther 2023;7(1):37–52. https://doi.org/10.1093/abt/tbad027; Franklin M.R., Platero S., Saini K.S. et al. Immuno-oncology trends: preclinical models, biomarkers, and clinical development. J Immunotherap Cancer 2022;10(1):e003231. https://doi.org/10.1136/jitc-2021-003231; Ferreira G.S., Veening-Griffioen D.H., Boon W.P.C. et al. Levelling the translational gap for animal to human efficacy data. Animals: an open access journal from MDPI 2020;10(7):1199. https://doi.org/10.3390/ani10071199; Costes L.M., Meresse B., Cerf-Bensussan N., Samsom J.N. The role of animal models in unravelling therapeutic targets in coeliac disease. Best Pract Res Clin Gastroenterol 2015;29(3): 437–50. https://doi.org/10.1016/j.bpg.2015.04.007; Tubau-Juni N., Hontecillas R., Ehrich M. et al. Preclinical Studies: Efficacy and Safety. In: Accelerated Path to Cures. 2018. P. 25–40. https://doi.org/10.1007/978-3-319-73238-1_3; Falchi L., Jardin F., Haioun C. et al. Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: preliminary safety and efficacy results. 2023, December 11. https://ash.confex.com/ash/2023/webprogram/Paper173953.html; Esfandiari A., Cassidy S., Webster R.M. Bispecific antibodies in oncology. Nat Rev Drug Discov 2022;21(6):411–2. https://doi.org/10.1038/d41573-022-00040-2; MSK ASH 2023 Insights: Promising Results for Bispecific Antibodies as. Memorial Sloan Kettering Cancer Center. 2023, December 11. https://www.mskcc.org/clinical-updates/msk-ash2023-insights-promising-results-for-bispecific-antibodies-as-firstline-therapies-for-patients-with-follicular-and-cell-lymphoma; Wu Y., Yi M., Zhu S. et al. Recent advances and challenges of bispecific antibodies in solid tumors. Exp Hematol Oncol 2021;10(1):56. https://doi.org/10.1186/s40164-021-00250-1; Challenges of Manufacturing the Expanding Range of Bi/ Multispecific Modalities. https://www.pharmasalmanac.com/articles/challenges-of-manufacturing-the-expanding-range-ofbimultispecific-modalities; Sun Y., Yu X., Wang X. et al. Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. Acta Pharm Sin B 2023;13(9):3583–97. https://doi.org/10.1016/j.apsb.2023.05.023; Ott P.A., Hodi F.S., Kaufman H.L. et al. Combination immunotherapy: a road map. J Immunotherap Cancer 2017;5:16. https://doi.org/10.1186/s40425-017-0218-5; You G., Won J., Lee Y. et al. Bispecific Antibodies: A smart arsenal for cancer immunotherapies. Vaccines 2021;9(7):724. https://doi.org/10.3390/vaccines9070724; Zhu S., Zhang T., Zheng L. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol 2021;14(1):156. https://doi.org/10.1186/s13045-021-01164-5; Bispecific Antibodies (n.d.). https://www.accc-cancer.org/home/learn/precision-medicine/treatment/bispecific-antibodies; Antibody therapeutics approved or in regulatory review in the EU or US – The Antibody Society. 2024, July 29. https://www.antibodysociety.org/resources/approved-antibodies/; Huang X., Zhu M., Chen R. et al. Innovative drugs promote precision cancer therapy. Clinical Cancer Bulletin 2023;2(1). https://doi.org/10.1007/s44272-023-00002-8; Powering the future of precision oncology medicine with big data. (2023). In: www.carislifesciences.com.

  8. 8
  9. 9
    Academic Journal

    Source: YASHIL IQTISODIYOT VA TARAQQIYOT; Vol. 3 No. 7 (2025): «Yashil iqtisodiyot va taraqqiyot» jurnali ; YASHIL IQTISODIYOT VA TARAQQIYOT; Том 3 № 7 (2025): «Yashil iqtisodiyot va taraqqiyot» журнали ; YASHIL IQTISODIYOT VA TARAQQIYOT; ##issue.vol## 3 ##issue.no## 7 (2025): «Yashil iqtisodiyot va taraqqiyot» журнали ; YASHIL IQTISODIYOT VA TARAQQIYOT; ##issue.vol## 3 ##issue.no## 7 (2025): «Yashil iqtisodiyot va taraqqiyot» jurnali ; 2992-8982 ; 0000-0000

    File Description: application/pdf

  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
    Academic Journal

    Source: Economic development and analysis; Vol. 2 No. 9 (2024): Economic Development and Analysis; 57-68 ; Экономическое развитие и анализ; Том 2 № 9 (2024): Экономическое развитие и анализ; 57-68 ; Iqtisodiy taraqqiyot va tahlil; Jild 2 № 9 (2024): Iqtisodiy taraqqiyot va tahlil; 57-68 ; 2992-877X ; 10.60078/2992-877X-2024-vol2-iss9

    File Description: application/pdf

  17. 17
  18. 18
    Academic Journal

    Source: Law, Economics and Management; 38-40 ; Актуальные вопросы экономики, права и социологии; 38-40

    File Description: text/html

    Relation: info:eu-repo/semantics/altIdentifier/isbn/978-5-907830-97-4; https://phsreda.com/e-articles/10651/Action10651-115300.pdf; Макроэкономические особенности перехода к режиму таргетирования инфляции в развитых странах [Электронный ресурс]. – Режим доступа: https://webeconomy.ru/index.php?page=cat&cat=mcat&mcat=137&type=news&p=2&newsid=2953 (дата обращения: 01.12.2022).; Сусленкова Е.Е. Политика инфляционного таргетирования: оценка эффективности в России и за рубежом / Е.Е. Сусленкова // Вестник евразийской науки. – 2023. – Т. 15. № s1. – С. 7 [Электронный ресурс]. – Режим доступа: https://esj.today/PDF/54FAVN123.pdf (дата обращения: 01.12.2022). EDN MKKVIT; Уровень инфляции в Канаде по годам [Электронный ресурс]. – Режим доступа: https://svspb.net/danmark/infljacija.php?l=kanada (дата обращения: 01.12.2024).; https://phsreda.com/article/115300/discussion_platform

  19. 19
    Academic Journal

    Source: Vestnik NSUEM; № 1 (2024); 101-113 ; Вестник НГУЭУ; № 1 (2024); 101-113 ; 2073-6495

    File Description: application/pdf

    Relation: https://nsuem.elpub.ru/jour/article/view/2452/1153; Баликоев В.З. Современная экономика России: М. Фридман против Дж. Кейнса // Вестник ТГУ. 2018. № 42.; URL: https://limex.me/profile/475952466/5002265/?showMore=1; Гартунг В. URL: https://avatars.dzeninfra.ru/get- (дата обращения: 25.09.2023).; Двинский К. URL: https://zenspisok.ru/politika/konstantin-dv; Глазьев С.Ю. Глазьев без цензуры: ЦБ блокирует экономический рост России. URL: Rutube≥телеканал Царьград (дата обращения: 18.09.2023).; Кочетов А. Россия предала последние западные идеалы. URL: https://Dzen.ru≥a/ZTkeUk7G2ILfLeh; О чем говорит показатель монетизации экономики? URL: https://iep.ru≥files/other/Gorunov_May_2023pop/ (дата обращения: 18.07.2023).; https://nsuem.elpub.ru/jour/article/view/2452

  20. 20
    Academic Journal

    Source: Research journal "The bulletin of the Far Eastern Federal University. Economics and Management"; № 4 (2023); 55-70 ; Научный журнал "Известия Дальневосточного федерального университета. Экономика и управление"; № 4 (2023); 55-70 ; 2413-9734 ; 2311-2271

    File Description: application/pdf